Tarsadia Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Tarsadia Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,000	Closed	-$235K	–	28
2020 Q3	$235K	Sell	20,000 -140,000	-88%	-$1.71M	0.02%	24
2020 Q2	$2.36M	Sell	160,000 -87,884	-35%	-$1.3M	0.42%	24
2020 Q1	$3.35M	Buy	+247,884	New	+$4.7M	0.32%	19

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Tarsadia Capital's AERI Position: Q4 2020 in Review

Tarsadia Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 20,000 shares — an estimated $235K sold.

Tarsadia Capital first reported a position in AERI in Q1 2020 and held it in 3 quarters. The position peaked at $3.35M in Q1 2020. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

Tarsadia Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Tarsadia Capital sold 20,000 Aerie Pharmaceuticals shares in Q4 2020, an estimated $235K.
Tarsadia Capital first reported a position in Aerie Pharmaceuticals in Q1 2020 and held it in 3 quarters.
Tarsadia Capital's Aerie Pharmaceuticals position peaked at $3.35M in Q1 2020.
150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on Tarsadia Capital's 13F filing for Q4 2020, filed 10 Feb 2021.